Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Cash from Financing Activities (2018 - 2025)

TransMedics has reported Cash from Financing Activities over the past 8 years, most recently at $3.1 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $3.1 million for Q4 2025, up 161.3% from a year ago — trailing twelve months through Dec 2025 was $16.9 million (down 26.3% YoY), and the annual figure for FY2025 was $16.9 million, down 26.3%.
  • Cash from Financing Activities for Q4 2025 was $3.1 million at TransMedics, down from $3.6 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for TMDX hit a ceiling of $394.0 million in Q2 2023 and a floor of $45000.0 in Q4 2021.
  • Median Cash from Financing Activities over the past 5 years was $3.0 million (2022), compared with a mean of $30.5 million.
  • Biggest five-year swings in Cash from Financing Activities: crashed 99.72% in 2021 and later surged 166150.21% in 2023.
  • TransMedics' Cash from Financing Activities stood at $45000.0 in 2021, then surged by 6711.11% to $3.1 million in 2022, then tumbled by 69.85% to $924000.0 in 2023, then grew by 28.35% to $1.2 million in 2024, then skyrocketed by 161.3% to $3.1 million in 2025.
  • The last three reported values for Cash from Financing Activities were $3.1 million (Q4 2025), $3.6 million (Q3 2025), and $7.1 million (Q2 2025) per Business Quant data.